trending Market Intelligence /marketintelligence/en/news-insights/trending/zug_dmrndzsndzszuaikaq2 content esgSubNav
In This List

AstraZeneca's blood disorder drug wins US FDA approval

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

AstraZeneca's blood disorder drug wins US FDA approval

The U.S. Food and Drug Administration approved AstraZeneca PLC's Lokelma to treat hyperkalemia in adults.

Hyperkalemia is a disorder characterized by high levels of potassium in the blood.

The approval for Lokelma, a highly selective, oral potassium-removing agent, is backed by three late-stage clinical studies. Data from one trial showed that 92% of patients on the drug achieved normal potassium levels within 48 hours from the start of the study.

In March, the European Commission approved Lokelma for the treatment of the same disease in adults.